VICTORIA-01

The VICTORIA-01 study is a Phase 1, open-label, dose escalation study of SOT201, a next-generation PD-1-targeting immunocytokine. The study will assess the safety, tolerability, and preliminary efficacy of SOT201 as a monotherapy for patients aged 18 years or above with advanced unresectable or metastatic solid tumors (NCT06163391). The trial will enroll patients at sites in the United States and EU.